October 2015: SMC decisions
The Scottish Medicines Consortium has approved the following medicines in NHS Scotland for particular indications: radium 223 (Xofigo; Bayer); ciclosporin (Ikervis; Santen); abiraterone (Zytiga; Janssen-Cilag). Nintedanib (Ofev; Boehringer Ingelheim), degludec/liraglutide (Xultophy; Novo Nordisk) and trastuzumab (Herceptin; Roche) have been accepted for restricted use and everolimus (Afinitor; Novartis) has not been recommended.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069544
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com